ERBB2 and breast cancer: Conversely, lapatinib has been shown to be effective in the metastatic setting in combination with capecitabine in patients with pretreated HER2+ breast cancer [21], and also in combination with letrozole for patients with HER2+ and hormone receptor (HR)-positive advanced disease [29].